+ All Categories
Home > Documents > MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE:...

MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE:...

Date post: 09-Oct-2020
Category:

Documents
Upload: others
View: 0 times
Download: 0 times
Download Report this document
Share this document with a friend
207
Transcript
Page 1: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 2: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 3: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 4: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 5: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 6: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 7: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 8: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 9: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 10: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 11: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 12: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 13: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 14: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 15: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 16: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 17: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 18: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 19: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 20: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 21: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 22: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 23: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 24: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 25: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 26: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 27: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 28: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 29: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 30: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 31: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 32: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 33: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 34: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 35: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 36: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 37: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 38: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 39: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 40: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 41: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 42: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 43: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 44: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 45: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 46: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 47: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 48: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 49: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 50: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 51: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 52: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 53: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 54: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 55: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 56: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 57: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 58: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 59: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 60: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 61: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 62: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 63: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 64: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 65: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 66: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 67: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 68: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 69: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 70: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 71: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 72: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 73: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 74: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 75: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 76: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 77: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 78: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 79: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 80: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 81: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 82: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 83: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 84: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 85: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 86: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 87: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 88: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 89: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 90: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 91: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 92: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 93: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 94: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 95: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 96: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 97: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 98: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 99: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 100: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 101: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 102: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 103: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 104: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 105: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 106: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 107: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 108: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 109: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 110: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 111: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 112: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 113: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 114: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 115: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 116: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 117: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 118: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 119: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 120: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 121: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 122: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 123: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 124: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 125: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 126: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 127: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 128: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 129: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 130: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 131: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 132: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 133: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 134: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 135: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 136: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 137: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 138: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 139: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 140: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 141: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 142: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 143: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 144: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 145: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 146: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 147: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 148: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 149: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 150: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 151: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 152: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 153: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 154: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 155: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 156: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 157: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 158: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 159: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 160: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 161: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 162: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 163: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 164: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 165: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 166: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 167: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 168: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 169: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 170: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 171: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 172: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 173: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 174: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 175: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 176: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 177: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 178: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 179: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 180: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 181: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 182: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 183: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 184: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 185: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 186: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 187: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 188: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 189: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 190: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 191: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 192: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 193: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 194: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 195: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 196: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 197: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 198: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 199: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 200: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 201: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 202: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 203: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 204: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 205: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 206: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9
Page 207: MDL 2179 Trial Docs · 2015. 1. 25. · symptoms in Exxon Valdez study respondents. SOURCE: Palinkas etal. 1993 25 15 10 Generalized p T SD CES- Odds Ratio 3.6 2.9 95% C. l. 2.2—5.9

Recommended
59 - MDL 2179 Trial Docs BOP Installations ... 10 API RP 53, Rl!COlItfIIended ... QONTROL (irm Etjltiptnent Systems Jor Drilling wells and API RJ> 64 ", ...

59 - MDL 2179 Trial Docs BOP Installations ... 10 API RP 53, Rl!COlItfIIended ... QONTROL (irm Etjltiptnent Systems Jor Drilling wells and API RJ> 64 ", ...

Documents

MDL 2179 Trial Docsmdl2179trialdocs.com/releases/release... · It is the responsibility of TODDI NAM and BP to ensure that HSE management systems are in place that enables all operations

MDL 2179 Trial Docsmdl2179trialdocs.com/releases/release... · It is the responsibility of TODDI NAM and BP to ensure that HSE management systems are in place that enables all operations

Documents

MDL 2179 Trial Docs · 2015-01-31 · and transition to the Installation, Hook-Up, and Commissioning (IHUC) team for managing all of the in-country activities and operations. Formation

MDL 2179 Trial Docs · 2015-01-31 · and transition to the Installation, Hook-Up, and Commissioning (IHUC) team for managing all of the in-country activities and operations. Formation

Documents

(BOP) CONTROL SYSTEM April 2000 - MDL 2179 Trial Docs

(BOP) CONTROL SYSTEM April 2000 - MDL 2179 Trial Docs

Documents

In Re: Oil Spill by the Oil Rig “Deepwater MDL NO. 2179 …gulfspillpunitivedamagessettlement.com/docs/Order Reasons.pdf · Class”)1 and the Plaintiffs’ Steering Committee (collectively,

In Re: Oil Spill by the Oil Rig “Deepwater MDL NO. 2179 …gulfspillpunitivedamagessettlement.com/docs/Order Reasons.pdf · Class”)1 and the Plaintiffs’ Steering Committee (collectively,

Documents

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF … · Halliburton, that party should explain, perhaps in addition to other things, (1) 1 Responses should be filed in the MDL 2179

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF … · Halliburton, that party should explain, perhaps in addition to other things, (1) 1 Responses should be filed in the MDL 2179

Documents

DAVID L. SUNDING - MDL 2179 Trial Docs · American Journal of Agricultural Economics, in press. “Impacts of Instream Flow Requirements for Freshwater Mussel Species in Texas,”

DAVID L. SUNDING - MDL 2179 Trial Docs · American Journal of Agricultural Economics, in press. “Impacts of Instream Flow Requirements for Freshwater Mussel Species in Texas,”

Documents

MDL 2179 Trial Docsmdl2179trialdocs.com/releases/release201303141200012/... · 2013. 3. 18. · 73909 Online Weigh-Up Sheet (Screen Shots from Viking) Request 73909 / Slurry 1 Test

MDL 2179 Trial Docsmdl2179trialdocs.com/releases/release201303141200012/... · 2013. 3. 18. · 73909 Online Weigh-Up Sheet (Screen Shots from Viking) Request 73909 / Slurry 1 Test

Documents

2177-2179 digests.pdf

2177-2179 digests.pdf

Documents

SHEAR RAM CAPABILITIES STUDY - MDL 2179 Trial Docs

SHEAR RAM CAPABILITIES STUDY - MDL 2179 Trial Docs

Documents

TREX-60413 - MDL 2179 Trial DocsThe 000 Ic the pioiiihl/ itt iPittOtittO floats Space api pthiitpi ii riOh/ ptitiheierit -tin te htrtirav sap ix trithee 05 rloirtea/ cat peta00 ion

TREX-60413 - MDL 2179 Trial DocsThe 000 Ic the pioiiihl/ itt iPittOtittO floats Space api pthiitpi ii riOh/ ptitiheierit -tin te htrtirav sap ix trithee 05 rloirtea/ cat peta00 ion

Documents

Lawrence A. Palinkas, PhD - UCLA CTSI

Lawrence A. Palinkas, PhD - UCLA CTSI

Documents

Horizon Handout 12_2… · MDL No. 2179 SECTION: J JUDGE BARBIER MAGISTRATE SHUSHAN MOTION FOR ADVERSE INFERENCES FROM ... PLAINTIFFS' STEERING COMMITTEE Brian H. Barr LEVIN, PAPANTONIO,

Horizon Handout 12_2… · MDL No. 2179 SECTION: J JUDGE BARBIER MAGISTRATE SHUSHAN MOTION FOR ADVERSE INFERENCES FROM ... PLAINTIFFS' STEERING COMMITTEE Brian H. Barr LEVIN, PAPANTONIO,

Documents

MDL 2179 Trial Docsmdl2179trialdocs.com/releases/release... · A systematic approach of integrating sonic/resistivity modeling, cutting/caving description, d-exponent, background

MDL 2179 Trial Docsmdl2179trialdocs.com/releases/release... · A systematic approach of integrating sonic/resistivity modeling, cutting/caving description, d-exponent, background

Documents

MDL 2179 Trial Docs - Phase Three · 2013. 3. 18. · order to balance frac gradients, pore pressures and ECD to achieve optimum slurry placement. The cement unit uses the Automatic

MDL 2179 Trial Docs - Phase Three · 2013. 3. 18. · order to balance frac gradients, pore pressures and ECD to achieve optimum slurry placement. The cement unit uses the Automatic

Documents

Report of Kenneth E. Arnold, PE, NAE - MDL 2179 Trial Docs · 2015-03-18 · No. 2:10-cv-04536. * MDLNo. 2179 * SECTION: J , * JUDGE BARBIER * MAGISTRATE JUDGE SHUSHAN Report of Kenneth

Report of Kenneth E. Arnold, PE, NAE - MDL 2179 Trial Docs · 2015-03-18 · No. 2:10-cv-04536. * MDLNo. 2179 * SECTION: J , * JUDGE BARBIER * MAGISTRATE JUDGE SHUSHAN Report of Kenneth

Documents

MDL 2179 Trial Docs

MDL 2179 Trial Docs

Documents

MDL 2179 Trial Docs · physiological and developmental penalties Potential mortality, especially during larval and juvenile stages Habitat loss, degradation or alteration Changes

MDL 2179 Trial Docs · physiological and developmental penalties Potential mortality, especially during larval and juvenile stages Habitat loss, degradation or alteration Changes

Documents